A large study highlights the risks associated with GLP-1 receptor agonist (RA) medications, commonly used in diabetes treatment and weight loss, particularly their link to neovascular age-related macular degeneration. Researchers at the University of Toronto analyzed over 1 million diabetic patients, discovering that those on GLP-1 RAs like semaglutide faced a doubled risk of developing serious vision issues after six months of usage. Extended use amplified this risk, particularly in older patients and those with prior strokes, underscoring the necessity for careful patient monitoring in diabetes treatment practices.
The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration.
A large-scale study has found that weight loss drugs could at least double the risk of diabetic patients developing age-related macular degeneration.
Researchers compared diabetes patients on GLP-1 RAs with those not using the drugs, revealing significant increases in the risk of neovascular age-related macular degeneration.
Diabetic patients who were older and/or had a stroke had an even higher risk, indicating a critical need for monitoring and management.
Collection
[
|
...
]